EGFR敏感突变晚期非小细胞肺癌一线治疗研究进展

Advances in first-line treatment of advanced non-small cell lung cancer with EGFR-sensitive mutations

分子靶向治疗是在驱动基因指导下的治疗,开启了非小细胞肺癌“个体化”与“精准”治疗时代。非小细胞肺癌驱动基因包括表皮生长因子受体(EGFR)、间变淋巴瘤激酶(ALK)和原癌基因-1(Ros-1)等。EGFR突变是非小细胞肺癌最常见的靶点,表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)是治疗EGFR突变晚期非小细胞肺癌的最有效药物,已广泛用于临床治疗,但后期耐药问题不可避免。近年来,为优化TKI治疗,EGFR-TKI联合治疗应运而生,不断探索有效的EGFR-TKI联合治疗的方案。如EGFR-TKI联合抗血管生成药物、化疗和免疫治疗等。本文就一线EGFR-TKI药物及EGFR-TKI联合治疗在一线探索的有关临床研究进展进行综述。

Molecular targeted therapy is a treatment under the guidance of driver genes,which has opened the era of"individualization"and"precision"treatment of non-small cell lung cancer.Non-small cell lung cancer driver genes include epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK)and proto-oncogene-1(Ros-1).EGFR mutation is the most common target of non-small cell lung cancer.Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)is the most effective drug for the treatment of EGFR mutation advanced non-small cell lung cancer.It has been widely used in clinical treatment.However,the problem of drug resistance in the later period is inevitable.In recent years,in order to optimize TKI treatment,EGFR-TKI combination therapy has emerged at the historic moment,and explore effective EGFR-TKI combination treatment options have been being explored continusly,such as EGFR-TKI combined with anti-angiogenic drugs,chemotherapy and immunotherapy.This article reviews the progress of clinical research on first-line EGFR-TKI drugs and EGFR-TKI combination therapy.